Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* H. pylori eradication (in combination with antibiotics)
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. Treatment duration for erosive esophagitis is typically 4-8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** 40 mg orally or intravenously twice daily, may be increased to 80 mg twice daily. Doses greater than 80 mg daily should be divided.
* **H. pylori Eradication:** 40 mg orally twice daily for 7-14 days in combination with specific antibiotics.
## Pediatric Dosing
* **GERD:**
* **1 month to < 5 years:** 1.1 mg/kg/day orally once daily, not to exceed 20 mg/day.
* **5 years to < 12 years:** 20 mg orally once daily.
* **12 years to 16 years:** 40 mg orally once daily.
* *Note: Intravenous dosing in pediatric patients is not well-established and should be guided by specialist consultation and institutional protocols.*
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose of 20 mg orally or 40 mg intravenously.
* **Renal Impairment:** No dose adjustment is typically required.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* Long-term use may be associated with: Vitamin B12 deficiency, hypomagnesemia, increased risk of Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine).
## Key Drug Interactions
* **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Consider alternative PPIs or spacing administration if concomitant use is necessary.
* **Drugs Dependent on Gastric pH:** May alter absorption of drugs like ketoconazole, itraconazole, atazanavir, nelfinavir, and digoxin.
* **Methotrexate:** May increase serum levels of methotrexate.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle spasms, tetany, seizures) especially with prolonged therapy (>1 year).
* Monitor for signs of C. difficile infection.
* Consider monitoring vitamin B12 levels with long-term therapy.
## Clinical Pearls
* Administer oral pantoprazole 30-60 minutes before a meal.
* IV formulation is stable for 24 hours at room temperature after reconstitution.
* Long-term use of PPIs should be reserved for patients with a clear indication and at the lowest effective dose.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace a thorough review of the current prescribing information and relevant literature. Always verify drug information with the most up-to-date resources.
